About: BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID‐19 therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID‐19 therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID‐19 therapy
Creator	August, Avery Huang, Weishan Mcgee, Michael
Source	Medline; PMC
abstract	Bruton's tyrosine kinase (BTK) signaling is involved in innate immune responses and regulates the production of proinflammatory cytokines that can contribute to COVID‐19 immunopathology. Clinical trials with BTK inhibitors in COVID‐19 treatment have been proposed, and previous studies have attempted to investigate the therapeutic effects of ibrutinib and underlying mechanisms in treating viral pneumonia. These attempts, however, did not consider potential off target effect of BTK inhibitors on T cell differentiation, function, and survival, which may be beneficial in treatment for COVID‐19. Here, we summarize the current knowledge of BTK/IL‐2‐inducible T‐cell kinase (ITK) signaling in immunopathology and lymphopenia and discuss the potential of BTK/ITK dual inhibitors such as ibrutinib in modulating immunopathology and lymphopenia, for COVID‐19 therapy.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1002/jlb.5covr0620-306r
bibo:pmid	32640487
has license	no-cc
sha1sum (hex)	d310f1ddc93bd3e06a70aaa90e762f99bf6407cf
schema:url	https://doi.org/10.1002/jlb.5covr0620-306r
resource representing a document's title	BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID‐19 therapy
has PubMed Central identifier	PMC7361550
has PubMed identifier	32640487
schema:publication	J Leukoc Biol
resource representing a document's body	covid:d310f1ddc93bd3e06a70aaa90e762f99bf6407cf#body_text
is schema:about of	named entity 'inhibitors' named entity 'studies' named entity 'BTK' named entity 'inhibitors' named entity 'differentiation' named entity 'T CELL DIFFERENTIATION' named entity 'IMMUNOPATHOLOGY' named entity 'POTENTIAL' named entity 'HERE' named entity 'TREATING' named entity 'DISCUSS' named entity 'KINASE' named entity '27S' named entity 'T-CELL' named entity 'ATTEMPTED' named entity 'THESE' named entity 'kinase' named entity 'signaling' named entity 'BTK' named entity 'tyrosine kinase' named entity 'COVID-19' named entity 'BTK' named entity 'ITK' named entity 'IL-2' named entity 'kinase' named entity 'T-cell' named entity 'Clinical trials' named entity 'ITK' named entity 'BTK' named entity 'COVID-19' named entity 'ITK' named entity 'bronchoalveolar lavage' named entity 'viral pneumonia' named entity 'ITK' named entity 'lung inflammation' named entity 'ibrutinib' named entity 'RT-qPCR' named entity 'CD4 +' named entity 'accelerated approval' named entity 'infection' named entity 'ITK' named entity 'CD8 +' named entity 'CD8 +' named entity 'US FDA' named entity 'infection' named entity 'adaptive immune response' named entity 'kinases' named entity 'MCL' named entity 'ibrutinib' named entity 'Lymphopenia' named entity 'BTK' named entity 'SARS-CoV-2' named entity 'T-cell' named entity 'BTK' named entity 'BTK inhibitor' named entity 'Nucleocapsid' named entity 'apoptosis' named entity 'infection' named entity 'COVID-19' named entity 'PBMCs' named entity 'macrophages' named entity 'cell apoptosis' named entity 'supplemental oxygen' named entity 'BTK' named entity 'CD8 +' named entity 'SARS-CoV-2' named entity 'zanubrutinib' named entity 'infection' named entity 'lymphocyte' named entity 'electron microscopy' named entity 'acalabrutinib' named entity 'acalabrutinib' named entity 'ITK' named entity 'ibrutinib' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'lymphopenia' named entity 'lymphocytes' named entity 'viral genome replication'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software